Lindbrook Capital »

4d Molecular Therapeutics In shares owned by Lindbrook Capital

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by Lindbrook Capital from 13F filings

Historical chart of Lindbrook Capital investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by Lindbrook Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by Lindbrook Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.2k 68 31.85
2023-12-31 $1.4k 68 20.26

More positions owned by Lindbrook Capital

Vanguard Total Stk Mkt Etf (VTI)
Vanguard Total Intl Stock Idex Etf Etf (VXUS)
Golub Cap Bdc Cef (GBDC)
Apple Stock (AAPL)
Spdr S&p 500 Etf Trust Etf (SPY)
Ishares Russell 1000 Growth Etf Etf (IWF)
Nvidia Corporation Stock (NVDA)
Microsoft Stock (MSFT)
Rpar Risk Parity Etf Etf (RPAR)
Ishares Russell 1000 Value Etf Etf (IWD)
Amazon.com Stock (AMZN)
Powershares Qqq Tr Etf (QQQ)
Oaktree Specialty Lending Corp Cef (OCSL)
Vertex Pharmaceuticals In Stock (VRTX)
Broadcom Stock (AVGO)

View all positions for Lindbrook Capital

Top funds holding 4d Molecular Therapeutics In

Viking Global Investors
RA Capital Management
BVF
VR Adviser
Henderson Group
Vanguard Group
Arrowpoint Asset Management
Casdin Capital
Goldman Sachs Group
Dimensional Fund Advisors
Deutsche Bank Aktiengesellschaft
Eagle Health Investments
Assenagon Asset Management
Jpmorgan Chase & Co
Point72 Asset Management

View all funds holding 4d Molecular Therapeutics In